What's Hot

View all perspectives
      RT @doctorRBC: Plenary session III:
      Intensive diet and exercise program in overweight/obese pts with knee OA showed sign

      Robert B Chao, MD doctorRBC

      2 years 5 months ago
      Plenary session III: Intensive diet and exercise program in overweight/obese pts with knee OA showed significant reduction in weight, pain and function, greater walk distance and quality of life. Abs#1675 @RheumNow #ACR22 https://t.co/vstfJahLQV
      RT @RichardPAConway: Bruce et al. Rheumatic disease onset/flare with ICI assoc good tumour response in melanoma. OR = 14

      Richard Conway RichardPAConway

      2 years 5 months ago
      Bruce et al. Rheumatic disease onset/flare with ICI assoc good tumour response in melanoma. OR = 14.151 @RheumNow #ACR22 Abstr#1668 https://t.co/870ODwva5n https://t.co/bcneKZbeC4
      RT @RichardPAConway: Bass et al. Treatment ICI-arthritis. Tricky one. MTX alone assoc longer time to cancer progression

      Richard Conway RichardPAConway

      2 years 5 months ago
      Bass et al. Treatment ICI-arthritis. Tricky one. MTX alone assoc longer time to cancer progression and to arthritis control compared to combination with bDMARD. Thoughts @drdavidliew ? @RheumNow #ACR22 Abstr#1669 https://t.co/8KH8RZzcaZ https://t.co/DtpA8s4PLy
      RT @doctorRBC: Are your SpA pts planning on conceiving? Be careful with NSAID use
      French study found age and NSAID use a

      Robert B Chao, MD doctorRBC

      2 years 5 months ago
      Are your SpA pts planning on conceiving? Be careful with NSAID use French study found age and NSAID use associated with longer time-to-conception. Factors not associated: smoking, BASDAI score, DMARD use #ACRBest Abs#1673 @RheumNow #ACR22 https://t.co/D63XTY7IB8
      RT @ericdeinmd: Ab1673 #ACR22: Time-to-Conception (T2C) in SpA
      Prosp, observ
      88F, 56 pregnancy
      Subfertility in 45% F, T2

      Eric Dein ericdeinmd

      2 years 5 months ago
      Ab1673 #ACR22: Time-to-Conception (T2C) in SpA Prosp, observ 88F, 56 pregnancy Subfertility in 45% F, T2C 16 mos Risks: age, NSAID Rx: NSAIDs (26%), steroids (9%), csDMARD (14%), biol (69%) No control grp - Is it cause or correlate? 2020 Repro G/L rec d/c NSAID @RheumNow #ACRBest https://t.co/e51XjhyH9u
      RT @RHEUMarampa: ☝️Treatment is the 3rd reason why we need to order a BL HRCT in pts with ILD; "We can't treat SSc-I

      sheila RHEUMarampa

      2 years 5 months ago
      ☝️Treatment is the 3rd reason why we need to order a BL HRCT in pts with ILD; "We can't treat SSc-ILD if we are not able to detect SSc-ILD" - Dr. Elana Bernstein #ACR @RheumNow #rheumatology https://t.co/ooZVSbt3Xf
      RT @synovialjoints: Peresolimab humanized IgG1 mab
      ➢ stimulates PD-1 & physiological immune inhibitory pathways
      âž

      Dr. Antoni Chan synovialjoints

      2 years 5 months ago
      Peresolimab humanized IgG1 mab ➢ stimulates PD-1 & physiological immune inhibitory pathways ➢ In RA phase 2 study, superior to placebo at Week 12 DAS28/CDAI ➢ safety events were similar between treatment groups Emery P #L03 https://t.co/4Jd79CW5RA #ACR22 #ACRBest @RheumNow https://t.co/PSuLQgjYuz
      RT @doctorRBC: BE OPTIMAL Study - Bimekizumab (IL-17A and IL-17F inhibitor) for treatment of PsA.
      Similar ACR 50 (~50%)

      Robert B Chao, MD doctorRBC

      2 years 5 months ago
      BE OPTIMAL Study - Bimekizumab (IL-17A and IL-17F inhibitor) for treatment of PsA. Similar ACR 50 (~50%) response rates of Bimekizumab, adalimumab, and placebo (switched to BKZ at wk 16). ~60% PASI100 in BKZ #ACRBest Abs#L02 @RheumNow #ACR22 https://t.co/W2B2kyju9F
      RT @RichardPAConway: Hamroun et al. Preconceptual NSAID use assoc impaired fertility in SpA, HR 3.01 for time-to-concept

      Richard Conway RichardPAConway

      2 years 5 months ago
      Hamroun et al. Preconceptual NSAID use assoc impaired fertility in SpA, HR 3.01 for time-to-conception @RheumNow #ACR22 Abstr#1673 https://t.co/jresR9MfXF https://t.co/flyfJob9un
      RT @DrCassySims: Congratulations @RheumNow @rheum_cat @CreakyJoints 🎉 #ACR22

      Catherine Sims, MD DrCassySims

      2 years 5 months ago
      Congratulations @RheumNow @rheum_cat @CreakyJoints 🎉 #ACR22 https://t.co/P7iLUPnt0p
      RT @ericdeinmd: Ab1674 #ACR22 HCQ in pregnancy is SAFE and Standard of Care!

      In Utero Exposure to HCQ does NOT ass w/

      Eric Dein ericdeinmd

      2 years 5 months ago
      Ab1674 #ACR22 HCQ in pregnancy is SAFE and Standard of Care! In Utero Exposure to HCQ does NOT ass w/ ocular toxicity: OCTs 5 yrs after birth 👀 PATCH study of HCQ to reduce CHB in pregnancy 18% CHB (historical) -> 7% treated risk OCT: retinal thickness nml at 5 yrs @RheumNow
      RT @KDAO2011: #CurbsideConsult. What would you do? 45 yo female with dSSc and ILD, had been on stable MMF 1500 mg bid. s

      TheDaoIndex KDAO2011

      2 years 5 months ago
      #CurbsideConsult. What would you do? 45 yo female with dSSc and ILD, had been on stable MMF 1500 mg bid. she had increased SOB, new dry cough, hand pain, stiffness.Exam noted synovitis, Labs: ESR 76, Echo RSVP 25 mmHg, HRCT increased ILD compared to a year ago. #ACR22 @rheumnow
      RT @drdavidliew: Are TNFi or IL-6Ri safe in rheumatic irAEs from ICI Rx?

      Multiple big US centers retrospective:
      TNFi, I

      David Liew drdavidliew

      2 years 5 months ago
      Are TNFi or IL-6Ri safe in rheumatic irAEs from ICI Rx? Multiple big US centers retrospective: TNFi, IL-6Ri vs MTX p>0.05, but may be approx 2x risk of cancer progression Has made me more cautious about TNFi, IL-6Ri - use MTX when you can Lovely work! ABST1669 #ACR22 @RheumNow https://t.co/cfAT1pQZ7I
      RT @KDAO2011: This is how Dr. Berstein manages SSc-ILD #ACR22 @rheumnow #CurbsideConsult https://t.co/vP7m0WpdK6

      TheDaoIndex KDAO2011

      2 years 5 months ago
      This is how Dr. Berstein manages SSc-ILD #ACR22 @rheumnow #CurbsideConsult https://t.co/vP7m0WpdK6
      RT @RichardPAConway: Abdel-Wahab et al. TCZ in combo with ipilimumab/nivolumab. Very preliminary results of what will be

      Richard Conway RichardPAConway

      2 years 5 months ago
      Abdel-Wahab et al. TCZ in combo with ipilimumab/nivolumab. Very preliminary results of what will be important trial. Appears safe and well-tolerated with no increased risk cancer progression. @RheumNow #ACR22 Abstr#1670 https://t.co/uPBnHJ9BRH

      Podcasts

      • Osteoarthritis Risky Business (4.18.2025)
      • EMR Messaging Woes (4.11.2025)
      • An Epidural Letdown (4.4.2025)

      Catch up on Conference Podcasts

      Key Conference Topics

      Additional Topics

      Filter by Type

      ×